Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.

Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.

Pediatr Blood Cancer. 2017 Dec 29;:

Authors: Theilen TM, Soerensen J, Bochennek K, Becker M, Schwabe D, Rolle U, Klingebiel T, Lehrnbecher T

Abstract
Inflammatory myofibroblastic tumor (IMT) and its subtype epithelioid inflammatory myofibroblastic sarcoma (EIMS) are rare soft-tissue tumors. As about 50% of IMT and 100% of EIMS contain activating rearrangements of the anaplastic lymphoma kinase (ALK) gene, targeted kinase inhibition of ALK by compounds such as crizotinib is a potential treatment option. We performed a literature review and analyzed a total of 30 patients with IMT/EIMS treated with crizotinib. A total of 12 patients achieved complete or partial remission. As preliminary data are promising, a prospective study evaluating crizotinib treatment in patients with unresectable/multifocal ALK+ IMT/EIMS is warranted.

PMID: 29286567 [PubMed - as supplied by publisher]

http://ift.tt/2CqkU48